Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma
Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

The combination of vorinostat, lenalidomide, and dexamethasone is active in heavily pretreated patients with multiple myeloma refractory to lenalidomide, a study published in the British Journal of Haematology has shown.1

In this single-center, open-label, phase 2b trial, researchers enrolled 25 patients with multiple myeloma refractory to lenalidomide. Patients were considered lenalidomide-refractory if they had no clinical response on a previous lenalidomide-containing regimen or if they experienced disease progression on or within 60 days of discontinuing a previous lenalidomide-containing regimen.

All participants received vorinostat 400 mg orally on days 1 to 7 and 15 to 21, lenalidomide 25 mg orally daily on days 1 to 21, and dexamethasone 40 mg on days 1, 8, 15, and 22 of each 28-day cycle.

Results showed that 24% of patients achieved an objective response, all of which were partial responses. Eighty percent of patients achieved stable disease or better.

Median time to a partial response was 1.9 months and median duration of response was 3.3 months. Researchers also found that median progression-free survival was 5.3 months.

The most frequently reported grade 3 to 4 adverse events were neutropenia, thrombocytopenia, anemia, and gastrointestinal toxicities.

Although these findings suggest that this regimen is active in lenalidomide-refractory patients, further evaluation is warranted to evaluate the efficacy and safety in a large, randomized controlled trial.

Reference

1. Sanchez L, Vesole DH, Richter JR, et al. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Br J Haematol. 2016 Nov 18. doi: 10.1111/bjh.14429. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs